Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer

• Published in: Molecular cancer therapeutics Vol. 20; no. 12; pp. 2420 - 2432
• Main Authors: Cruz-Collazo, Ailed, Ruiz-Calderon, Jean F, Picon, Hector, Borrero-Garcia, Luis D, Lopez, Irmaris, Castillo-Pichardo, Linette, Del Mar Maldonado, Maria, Duconge, Jorge, Medina, Julia I, Bayro, Marvin J, Hernández-O'Farrill, Eliud, Vlaar, Cornelis P, Dharmawardhane, Suranganie
• Format: Journal Article
• Language: English
• Published: United States 01-12-2021
• Subjects: Animals; cdc42 GTP-Binding Protein - antagonists & inhibitors; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Humans; Mice; Mice, SCID; rac1 GTP-Binding Protein - antagonists & inhibitors; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - pathology
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.MCT-21-0348

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer, with a high predisposition for locally invasive and metastatic cancer. With the objective to reduce cancer metastasis, we developed small molecule inhibitors to target the drivers of metastasis, the Rho GTPases Rac and Cdc42. Of these, MBQ-167 inhibits both Rac and Cdc42 with IC
s of 103 and 78 nmol/L, respectively; and consequently, inhibits p21-activated kinase (PAK) signaling, metastatic cancer cell proliferation, migration, and mammosphere growth; induces cell-cycle arrest and apoptosis; and decreases HER2-type mammary fatpad tumor growth and metastasis (Humphries-Bickley and colleagues, 2017). Herein, we used nuclear magnetic resonance to show that MBQ-167 directly interacts with Rac1 to displace specific amino acids, and consequently inhibits Rac.GTP loading and viability in TNBC cell lines. Phosphokinome arrays in the MDA-MB-231 human TNBC cells show that phosphorylation status of kinases independent of the Rac/Cdc42/PAK pathway are not significantly changed following 200 nmol/L MBQ-167 treatment. Western blotting shows that initial increases in phospho-c-Jun and phospho-CREB in response to MBQ-167 are not sustained with prolonged exposure, as also confirmed by a decrease in their transcriptional targets. MBQ-167 inhibits tumor growth, and spontaneous and experimental metastasis in immunocompromised (human TNBC) and immunocompetent (mouse TNBC) models. Moreover, per oral administration of MBQ-167 at 100 mg/kg body weight is not toxic to immunocompetent BALB/c mice and has a half-life of 4.6 hours in plasma. These results highlight the specificity, potency, and bioavailability of MBQ-167, and support its clinical potential as a TNBC therapeutic.